Immunomodulatory progenitor cell therapy (Celixir)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameImmunomodulatory progenitor cell therapy (Celixir)
Drug Alias NameiMP-cells免疫调节祖细胞疗法-CelixiriMP cell therapyHeartcel
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Immunomodulatory progenitor cell therapy
Mechanisms of ActionLeukocyte common antigen modulatorsEpidermal growth factor receptor erbB1 modulatorsImmunomodulators +[4] 
TargetsLeukocyte common antigenMajor histocompatibility complex IIEpidermal growth factor receptor erbB1
Therapy Area/IndicationsEndomyocardial FibrosisCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelixir
China Registration ClassN/A

Develop Information

Active CompaniesCelixir
Inactive CompaniesCell Therapy Ltd
Active IndicationsCardiomyopathies
Inactive IndicationsEndomyocardial Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A